Jump to content

Savolitinib

Edit links
From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Savolitinib
Clinical data
Other namesVolitinib
Identifiers
  • 3-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
CAS Number
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.238.920 Edit this at Wikidata
Chemical and physical data
FormulaC17H15N9
Molar mass345.370 g·mol−1
3D model (JSmol)
  • C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
  • InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
  • Key:XYDNMOZJKOGZLS-NSHDSACASA-N

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2] It has been given conditional approval for these indication in China.[3]

References

  1. ^ "Savolitinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
  2. ^ "Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG.
  3. ^ Markham A (September 2021). "Savolitinib: First Approval". Drugs. 81 (14): 1665–1670. doi:10.1007/s40265-021-01584-0. PMID 34455538. S2CID 237344020.
  • "Savolitinib". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Savolitinib&oldid=1223011742"